Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 177.50
Bid: 170.00
Ask: 185.00
Change: -2.50 (-1.39%)
Spread: 15.00 (8.824%)
Open: 180.00
High: 182.50
Low: 177.50
Prev. Close: 180.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Faron Pharmaceuticals Directors Buy Shares

Thu, 21st Jun 2018 16:31

LONDON (Alliance News) - Faron Pharmaceuticals Oy said on Thursday several directors purchased shares over the course of three days from Tuesday to Thursday.

On Tuesday, Non-Executive Director Matti Manner and a person closely associated purchased 22,900 shares in total at a price of 56 pence per share for GBP12,824.

On Wednesday, Chief Financial Officer Yrjo Wichmann bought 5,200 shares for 67 pence each for GBP3,484. On Thursday, Corporate Legal Counsel Pessi Honkasalo acquired 1,500 shares for 75p per share for GBP1,125.

Medical Director Matti Karvonon and a closely associated person purchased 15,000 shares at a price of 56p and 31,000 shares at 57p respectively on Thursday for GBP

Also on Thursday, Chief Executive Markku Jalkanen and a closely associated person bought a total of 36,000 shares for 71p, and Chief Development Officer Juho Jalkanen acquired 12,000 shares for the same price.

It has not been disclosed how many shares any of these directors now hold following these transactions.

Shares in the pharmaceutical company closed down 2.7% on Thursday at 72.00p.

More News
9 Mar 2020 14:07

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Read more
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more
5 Mar 2020 14:28

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Read more
2 Mar 2020 12:04

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Read more
2 Mar 2020 10:08

Faron Pharmaceuticals acquires rights to AOC3 inhibitors

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.

Read more
6 Feb 2020 14:17

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Read more
27 Jan 2020 11:22

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Read more
13 Jan 2020 11:54

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Read more
30 Dec 2019 15:39

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

Read more
30 Dec 2019 10:56

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Read more
11 Dec 2019 13:42

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

Read more
11 Dec 2019 10:45

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Read more
29 Nov 2019 10:23

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Read more
28 Nov 2019 11:56

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Read more
21 Nov 2019 12:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.